The DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Diabetic neuropathy
Abstract
The global epidemic of prediabetes and diabetes has led to a corresponding epidemic of complications of these disorders. The most prevalent complication is neuropathy, of which distal symmetric polyneuropathy (for the purpose of this Primer, referred to as diabetic neuropathy) is very common. Diabetic neuropathy is a loss of sensory function beginning distally in the lower extremities that is also characterized by pain and substantial morbidity. Over time, at least 50% of individuals with diabetes develop diabetic neuropathy. Glucose control effectively halts the progression of diabetic neuropathy in patients with type 1 diabetes mellitus, but the effects are more modest in those with type 2 diabetes mellitus. These findings have led to new efforts to understand the aetiology of diabetic neuropathy, along with new 2017 recommendations on approaches to prevent and treat this disorder that are specific for each type of diabetes. In parallel, new guidelines for the treatment of painful diabetic neuropathy using distinct classes of drugs, with an emphasis on avoiding opioid use, have been issued. Although our understanding of the complexities of diabetic neuropathy has substantially evolved over the past decade, the distinct mechanisms underlying neuropathy in type 1 and type 2 diabetes remains unknown. Future discoveries on disease pathogenesis will be crucial to successfully address all aspects of diabetic neuropathy, from prevention to treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diabetic neuropathy involves various syndromes, such as mono- and polyneuropathies, plexopathies, radiculopathies and autonomic neuropathy, among which distal symmetric polyneuropathy is very prevalent (108).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [108]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,379
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Central sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Research works printed but not linked: 5
- International Diabetes Federation. IDF Diabetes Atlas - 8th edition: key messages. IDF https://diabetesatlas.org/key-messages.html (2019).
- Callaghan, B. C., Little, A. A., Feldman, E. L. & Hughes, R. A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev. 6, CD007543 (2012). This analysis of clinical studies evaluating the impact of glycaemic control on neuropathy outcomes in T1DM and T2DM reveals that enhanced glucose control significantly attenuates neuropathy development in T1DM but not in T2DM.
- Moore, R. A., Straube, S., Wiffen, P. J., Derry, S. & McQuay, H. J. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst. Rev. 8, CD007076 (2009).
- Derry, S., Wiffen, P. J., Aldington, D. & Moore, R. A. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst. Rev. 1, CD011209 (2015).
- Amalraj, M. J., Anitha Rani, A. & Viswanathan, V. A study on positive impact of intensive psychological counseling on psychological well-being of type 2 diabetic patients undergoing amputation. Int. J. Psychol. Couns. 9, 10–16 (2017).
Cited by
Sorted by citations
Jensen, T. S., Karlsson, P., Gylfadottir, S. S., Andersen, S. T., Bennett, D. L., Tankisi, H., Finnerup, N. B., Terkelsen, A. J., Khan, K., Themistocleous, A. C., et al. (2021) · Brain · doi:10.1093/brain/awab079 · Cited by 265
Self-citationAntiproliferative and palliative activity of flavonoids in colorectal cancer
Fernández, J., Silván, B., Entrialgo-Cadierno, R., Villar, C. J., Capasso, R., Uranga, J. A., Lombó, F., & Abalo, R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112241 · Cited by 258
Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors
Vettoretti, M., Cappon, G., Facchinetti, A., & Sparacino, G. (2020) · Sensors · doi:10.3390/s20143870 · Cited by 176
Extracellular matrix-inspired biomaterials for wound healing
Hosty, L., Heatherington, T., Quondamatteo, F., & Browne, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09750-9 · Cited by 63
Pai, Y.-W., Tang, C.-L., Lin, C.-H., Lin, S.-Y., Lee, I.-T., & Chang, M.-H. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.004 · Cited by 20
Zhu, H.-M., Liu, N., Sun, D.-X., & Luo, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202298 · Cited by 12
Metadata
- Authors
- Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V.
- Affiliations
- University of Michigan (US)
- University of Alberta (CA)
- University of Kansas Medical Center (US)
- University of Oxford (GB)
- University Health Network (CA)
- VA Maryland Health Care System (US)
- M.V. Hospital for Diabetes and Diabetes Research Centre (IN)
- Corresponding author
- Feldman, Eva L.
- ORCID
- Venue
- Nature Reviews Disease Primers
- Published
- 2019-06-13
- Volume
- 5
- Issue
- 1
- Pages
- 41-41
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4211145818
- Cited by
- 1,697
- References
- 225
- Citations by year
- 2026: 246 · 2025: 337 · 2024: 364 · 2023: 272 · 2022: 220 · 2021: 149 · 2020: 78 · 2019: 13
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Disease Primers (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (101RX001030)
- Diabetes Action Research and Education Foundation
- Wellcome Trust (102645, 102645/Z/13/Z, 202747/Z/16/Z, 202747/Z/16/)
- Diabetes Canada
- European Commission (HORIZON2020)
- Novo Nordisk Fonden (NNF14OC0011633)
- National Institutes of Health (R01D107956)
- Clinical Science Research and Development
- Geriatric Research Education and Clinical Center
- Canadian Institutes of Health Research
- National Institute of Diabetes and Digestive and Kidney Diseases (R24DK082841, R01DK115687, R01DK107007)
- National Institute of Neurological Disorders and Stroke (K23NS079417)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Keywords
- diabetic neuropathy, distal symmetric polyneuropathy, type 1 diabetes, type 2 diabetes, glycemic control, prediabetes, neuropathic pain, neuropathy prevention, neuropathy treatment, opioid avoidance, pathogenesis
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Analgesics, Opioid, Diabetic Neuropathies, Humans, Hyperglycemia, Hyperlipidemias, Mass Screening, Quality of Life, Risk Factors, Prevalence, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
